Hi,
moomoo ID:NaN
Log Out
ENGLISH
  • ENGLISH
  • 中文繁体
  • 中文简体
donwloadimg

Download App

Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Moomoo > Quotes > SYK Stryker Corp > Key Indicators
SYK Stryker Corp
206.930
-1.950-0.93%
Post Mkt Price
206.9300.0000.00%
YOY
Do not show
Hide blank lines
(Q2)2022/06/30(Q1)2022/03/31(FY)2021/12/31(Q4)2021/12/31
Financial Ratios
Efficiency Ratios TTM
Cash Conversion Cycle(D)
-7.39% 208.0951 -13.75% 209.3135 -18.84% 205.7721 -18.84% 205.7721
Receivable Turnover(T)
-8.93% 6.0178 11.15% 6.2172 16.52% 5.9787 16.52% 5.9787
Inventory Turnover(T)
5.57% 1.7777 11.09% 1.7825 15.44% 1.8038 15.44% 1.8038
Fixed Assets Turnover(T)
3.11% 6.3631 14.44% 6.3347 13.53% 6.1264 13.53% 6.1264
Total Asset Rate(T)
1.43% 0.5056 7.04% 0.5009 11.49% 0.4962 11.49% 0.4962
ROIC
-6.26% 7.476% 28.93% 7.233% 16.78% 7.327% 16.78% 7.327%
ROE
-10.07% 14.098% 33.43% 14.117% 15.47% 14.263% 15.47% 14.263%
ROA
-6.7% 5.963% 29.34% 5.791% 16.63% 5.783% 16.63% 5.783%
FCF to Sales
-35.93% 11.725% -23.63% 14.073% -17.68% 16.004% -17.68% 16.004%
FCF to Net Income
-30.34% 99.423% -36.8% 121.737% -21.3% 137.312% -21.3% 137.312%
Efficiency Ratios
ROE 5 Year Average
-- -- -- -- -4.38% 17.360% -- --
ROA 5 Year Average
-- -- -- -- -7.92% 7.432% -- --
Average 5 Years ROIC
-- -- -- -- -7.88% 9.429% -- --
Profitability Ratios TTM
Gross Margin
-0.9% 63.798% 2.33% 64.217% 1.58% 64.110% 1.58% 64.110%
Operating Margin
-15.87% 15.038% 9.12% 15.393% 0.62% 15.706% 0.62% 15.706%
Net Margin
-8.02% 11.793% 20.83% 11.561% 4.61% 11.655% 4.61% 11.655%
EBITDA Margin
-13.19% 0.2053% 3.59% 0.2088% 1.06% 0.2149% 1.06% 0.2149%
R & D Expense Ratio
17.95% 7.950% 12.72% 7.800% 5.25% 7.220% 5.25% 7.220%
Sales Expense Ratio
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Administration Expense Rate
-- 0.000% -- 0.000% -- 0.000% -- 0.000%
Financial Health Ratios
Long-Term Debt to Equity Ratio
-7.4% 85.326% -4.59% 92.284% -17.09% 83.834% -17.09% 83.834%
Total Assets to Common Equity
-5.72% 229.884% -3.07% 240.177% -11.28% 232.782% -11.28% 232.782%
Debt to Asset Ratio
-7.39% 85.371% -3.23% 93.706% -21.56% 83.881% -21.56% 83.881%
Current Ratio
-5.66% 2.0039 -12.86% 1.9794 14.35% 2.202 14.35% 2.202
Quick Ratio
-18.15% 0.97 -17.73% 1.0256 16.93% 1.328 16.93% 1.328
GrowthRatios
Growth Ratios
Revenue CAGR(3Y)
-- -- -- -- 63.26% 7.947% -- --
Revenue CAGR(5Y)
-- -- -- -- 13.04% 8.601% -- --
Net Income CAGR(3Y)
-- -- -- -- -208.34% -17.515% -- --
Net Income CAGR(5Y)
-- -- -- -- 82.91% 3.898% -- --
Dividend CAGR(3Y)
-- -- -- -- -2.65% 10.230% -- --
Dividend CAGR(5Y)
-- -- -- -- -1.56% 10.558% -- --
FCF 1 Year Growth
-- -- -- -- -102.3% -1.864% -- --
FCF CAGR(3Y)
-- -- -- -- -75.75% 10.343% -- --
FCF CAGR(5Y)
-- -- -- -- -54.84% 15.675% -- --
Currency Unit
USDUSDUSDUSD

FY: Financial Year Annual Report, which is equivalent to the 10-K file disclosed by the listed company to the SEC.

Q: Quarterly report, which is equivalent to the 10-Q file disclosed by the listed company to the SEC, where Q1, Q2, Q3, and Q4 are single quarterly reports with a span of 3 months; Q6 and Q9 are cumulative quarterly reports, and Q6 is 6 months , Q9 is 9 months.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
Stryker Corp. operates as a medical technology company. It operates through the following segments: Orthopaedics & Spine and MedSurg & Neurotechnology. The Orthopaedics & Spine segment provides implants for use in total joint replacements, such as hip, knee, and shoulder, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical and thoracolumbar systems that are used in spinal injury, complex spine and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment, patient & caregiver safety technologies, and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques, products for brain and open skull based surgical procedures, orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products, minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke, and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company was founded by Homer H. Stryker in 1941 and is headquartered in Kalamazoo, MI.
CEO: Mr. Kevin A. Lobo
Market: NYSE
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...